<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39388490</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>10</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV2 mRNA vaccine intravenous administration induces myocarditis in chronic inflammation.</ArticleTitle><Pagination><StartPage>e0311726</StartPage><MedlinePgn>e0311726</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0311726</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0311726</ELocationID><Abstract><AbstractText>The current COVID-19 mRNA vaccines were developed and applied for pandemic-emergent conditions. These vaccines use a small piece of the virus's genetic material (mRNA) to stimulate an immune response against COVID-19. However, their potential effects on individuals with chronic inflammatory conditions and vaccination routes remain questionable. Therefore, we investigated the effects of mRNA vaccines in a mouse model of chronic inflammation, focusing on their cardiac toxicity and immunogenicity dependent on the injection route. mRNA vaccine intravenous administration with or without chronic inflammation exacerbated cardiac pericarditis and myocarditis; immunization induced mild inflammation and inflammatory cytokine IL-1beta and IL-6 production in the heart. Further, IV mRNA vaccination induced cardiac damage in LPS chronic inflammation, particularly serum troponin I (TnI), which dramatically increased. IV vaccine administration may induce more cardiotoxicity in chronic inflammation. These findings highlight the need for further research to understand the underlying mechanisms of mRNA vaccines with chronic inflammatory conditions dependent on injection routes.</AbstractText><CopyrightInformation>Copyright: Â© 2024 Jeon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Ha-Eun</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, Jungwon University, Goesan-gun, Chungbuk, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seonghyun</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0003-7355-3570</Identifier><AffiliationInfo><Affiliation>Department of Medical and Biological Sciences, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biotechnology, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jisun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical and Biological Sciences, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roh</LastName><ForeName>Gahyun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medical and Biological Sciences, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biotechnology, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hyo-Jung</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Medical and Biological Sciences, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biotechnology, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yu-Sun</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Medical and Biological Sciences, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biotechnology, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yeon-Jung</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Medical and Biological Sciences, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biotechnology, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hong-Ki</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, Jungwon University, Goesan-gun, Chungbuk, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Ji-Hwa</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, Jungwon University, Goesan-gun, Chungbuk, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>You-Jeung</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Samsung Medical Center, 50 Irwon Dong, Gangnam-gu, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil</LastName><ForeName>Chae-Ok</ForeName><Initials>CO</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Samsung Medical Center, 50 Irwon Dong, Gangnam-gu, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Eun-Seok</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Samsung Medical Center, 50 Irwon Dong, Gangnam-gu, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nam</LastName><ForeName>Jae-Hwan</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Medical and Biological Sciences, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biotechnology, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SML Biopharm, Gyeonggi-do, Gwangmyeong, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Byung-Kwan</ForeName><Initials>BK</Initials><Identifier Source="ORCID">0000-0003-3974-1175</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Science, Jungwon University, Goesan-gun, Chungbuk, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019210">Troponin I</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="Y">mRNA Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019210" MajorTopicYN="N">Troponin I</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>22</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>13</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39388490</ArticleId><ArticleId IdType="pmc">PMC11469607</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0311726</ArticleId><ArticleId IdType="pii">PONE-D-24-04623</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603â15. Epub 2020/12/11. doi: 10.1056/NEJMoa2034577 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403â16. Epub 2020/12/31. doi: 10.1056/NEJMoa2035389 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, Lu G, Tan S, Xia J, Xiong H, Yu X, et al.. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 2020;30(10):936â9. Epub 2020/08/18. doi: 10.1038/s41422-020-00392-7 [pii] 392 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-00392-7</ArticleId><ArticleId IdType="pmc">PMC7429369</ArticleId><ArticleId IdType="pubmed">32801356</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al.. The Advisory Committee on Immunization Practicesâ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 VaccineâUnited States, December 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1922â4. Epub 2020/12/18. doi: 10.15585/mmwr.mm6950e2 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6950e2</ArticleId><ArticleId IdType="pmc">PMC7745957</ArticleId><ArticleId IdType="pubmed">33332292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong EZ, Koh CWT, Tng DJH, Ooi JSG, Yee JX, Chew VSY, et al.. RNase2 is a possible trigger of acute-on-chronic inflammation leading to mRNA vaccine-associated cardiac complication. Med. 2023;4(6):353â60 e2. Epub 2023/04/28. doi: 10.1016/j.medj.2023.04.001 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2023.04.001</ArticleId><ArticleId IdType="pmc">PMC10131284</ArticleId><ArticleId IdType="pubmed">37105176</ArticleId></ArticleIdList></Reference><Reference><Citation>Faizo AA, Qashqari FS, El-Kafrawy SA, Barasheed O, Almashjary MN, Alfelali M, et al.. A potential association between obesity and reduced effectiveness of COVID-19 vaccine-induced neutralizing humoral immunity. J Med Virol. 2023;95(1):e28130. Epub 2022/09/07. doi: 10.1002/jmv.28130 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28130</ArticleId><ArticleId IdType="pmc">PMC9539352</ArticleId><ArticleId IdType="pubmed">36068377</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, et al.. Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document. Circ Heart Fail. 2020;13(11):e007405. Epub 2020/11/13. doi: 10.1161/CIRCHEARTFAILURE.120.007405 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.120.007405</ArticleId><ArticleId IdType="pmc">PMC7673642</ArticleId><ArticleId IdType="pubmed">33176455</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman AM, McNamara D. Myocarditis. N Engl J Med. 2000;343(19):1388â98. doi: 10.1056/NEJM200011093431908 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200011093431908</ArticleId><ArticleId IdType="pubmed">11070105</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff JF. Viral myocarditis. A review. Am J Pathol. 1980;101(2):425â84. .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1903609</ArticleId><ArticleId IdType="pubmed">6254364</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim BK, Peter AK, Xiong D, Narezkina A, Yung A, Dalton ND, et al.. Inhibition of Coxsackievirus-associated dystrophin cleavage prevents cardiomyopathy. J Clin Invest. 2013;123(12):5146â51. Epub 2013/11/10. doi: 10.1172/JCI66271 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI66271</ArticleId><ArticleId IdType="pmc">PMC3859391</ArticleId><ArticleId IdType="pubmed">24200690</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt B, Kamat I, Hotez PJ. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021;144(6):471â84. Epub 2021/07/21. doi: 10.1161/CIRCULATIONAHA.121.056135 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.056135</ArticleId><ArticleId IdType="pmc">PMC8340726</ArticleId><ArticleId IdType="pubmed">34281357</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, et al.. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol. 2021;6(10):1202â6. Epub 2021/06/30. doi: 10.1001/jamacardio.2021.2833 [pii] hbr210004 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2021.2833</ArticleId><ArticleId IdType="pmc">PMC8243257</ArticleId><ArticleId IdType="pubmed">34185045</ArticleId></ArticleIdList></Reference><Reference><Citation>Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, et al.. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization PracticesâUnited States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(27):977â82. Epub 2021/07/09. doi: 10.15585/mmwr.mm7027e2 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7027e2</ArticleId><ArticleId IdType="pmc">PMC8312754</ArticleId><ArticleId IdType="pubmed">34237049</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser M, Agdamag ACC, Maharaj VR, Mutschler M, Charpentier V, Chowdhury M, et al.. COVID-19-Associated Myocarditis: An Evolving Concern in Cardiology and Beyond. Biology (Basel). 2022;11(4). Epub 2022/04/24. doi: 10.3390/biology11040520 [pii] biology-11-00520 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology11040520</ArticleId><ArticleId IdType="pmc">PMC9025425</ArticleId><ArticleId IdType="pubmed">35453718</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S, Caminiti C, Giordano R, Argentiero A, Ramundo G, Principi N. Myocarditis Following COVID-19 Vaccine Use: Can It Play a Role for Conditioning Immunization Schedules? Front Immunol. 2022;13:915580. Epub 2022/07/15. doi: 10.3389/fimmu.2022.915580 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.915580</ArticleId><ArticleId IdType="pmc">PMC9271782</ArticleId><ArticleId IdType="pubmed">35833128</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Chen Y, Zhao Y, Christopher Lung D, Ye Z, Song W, et al.. Corrigendum to: Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model. Clin Infect Dis. 2021;73(12):2372â3. Epub 2021/12/02. doi: 10.1093/cid/ciab941 [pii] ciab941 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab941</ArticleId><ArticleId IdType="pmc">PMC8690168</ArticleId><ArticleId IdType="pubmed">34849654</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA Vaccines for Infectious Diseases. Front Immunol. 2019;10:594. Epub 2019/04/12. doi: 10.3389/fimmu.2019.00594 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00594</ArticleId><ArticleId IdType="pmc">PMC6446947</ArticleId><ArticleId IdType="pubmed">30972078</ArticleId></ArticleIdList></Reference><Reference><Citation>Park HJ, Bang YJ, Kwon SP, Kwak W, Park SI, Roh G, et al.. Analyzing immune responses to varied mRNA and protein vaccine sequences. NPJ Vaccines. 2023;8(1):84. Epub 2023/06/05. doi: 10.1038/s41541-023-00684-0 [pii] 684 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00684-0</ArticleId><ArticleId IdType="pmc">PMC10239716</ArticleId><ArticleId IdType="pubmed">37271785</ArticleId></ArticleIdList></Reference><Reference><Citation>Belliveau NM, Huft J, Lin PJ, Chen S, Leung AK, Leaver TJ, et al.. Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. Mol Ther Nucleic Acids. 2012;1(8):e37. Epub 2013/01/25. doi: 10.1038/mtna.2012.28 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtna.2012.28</ArticleId><ArticleId IdType="pmc">PMC3442367</ArticleId><ArticleId IdType="pubmed">23344179</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn SY, Sohn SH, Lee SY, Park HL, Park YW, Kim H, et al.. The effect of lipopolysaccharide-induced obesity and its chronic inflammation on influenza virus-related pathology. Environ Toxicol Pharmacol. 2015;40(3):924â30. Epub 2015/10/29. doi: 10.1016/j.etap.2015.09.020 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.etap.2015.09.020</ArticleId><ArticleId IdType="pubmed">26509733</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim BK, Yun SH, Ju ES, Kim BK, Lee YJ, Yoo DK, et al.. Soluble coxsackievirus B3 3C protease inhibitor prevents cardiomyopathy in an experimental chronic myocarditis murine model. Virus research. 2015;199:1â8. doi: 10.1016/j.virusres.2014.11.030 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2014.11.030</ArticleId><ArticleId IdType="pubmed">25485472</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, Wang M, Lin W, Cai Q, Zhang L, Chen D, et al.. Cardiac biomarkers, cardiac injury, and comorbidities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Immun Inflamm Dis. 2021;9(4):1071â100. Epub 2021/08/19. doi: 10.1002/iid3.471 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.471</ArticleId><ArticleId IdType="pmc">PMC8427124</ArticleId><ArticleId IdType="pubmed">34405950</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HW, Jenista ER, Wendell DC, Azevedo CF, Campbell MJ, Darty SN, et al.. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol. 2021;6(10):1196â201. Epub 2021/06/30. doi: 10.1001/jamacardio.2021.2828 [pii] hbr210003 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2021.2828</ArticleId><ArticleId IdType="pmc">PMC8243258</ArticleId><ArticleId IdType="pubmed">34185046</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu Mouch S, Roguin A, Hellou E, Ishai A, Shoshan U, Mahamid L, et al.. Myocarditis following COVID-19 mRNA vaccination. Vaccine. 2021;39(29):3790â3. Epub 2021/06/08. doi: 10.1016/j.vaccine.2021.05.087 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.05.087</ArticleId><ArticleId IdType="pmc">PMC8162819</ArticleId><ArticleId IdType="pubmed">34092429</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon D, Tascilar K, Fagni F, Kronke G, Kleyer A, Meder C, et al.. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 2021;80(10):1312â6. Epub 2021/05/08. doi: 10.1136/annrheumdis-2021-220461 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220461</ArticleId><ArticleId IdType="pmc">PMC8103562</ArticleId><ArticleId IdType="pubmed">33958324</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003;112(12):1785â8. Epub 2003/12/18. doi: 10.1172/JCI20514 [pii] 20514 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI20514</ArticleId><ArticleId IdType="pmc">PMC297006</ArticleId><ArticleId IdType="pubmed">14679172</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357(19):1903â15. Epub 2007/11/09. doi: 10.1056/NEJMoa066092 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa066092</ArticleId><ArticleId IdType="pubmed">17989383</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlton KU. Insights From a Murine Model of Coronavirus Disease 2019 (COVID-19) mRNA Vaccination-Induced Myopericarditis: Could Accidental Intravenous Vaccine Injection Induce Myopericarditis? Clin Infect Dis. 2022;74(11):1951â2. Epub 2021/08/29. doi: 10.1093/cid/ciab741 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab741</ArticleId><ArticleId IdType="pubmed">34453510</ArticleId></ArticleIdList></Reference><Reference><Citation>Krauson AJ, Casimero FVC, Siddiquee Z, Stone JR. Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients. NPJ Vaccines. 2023;8(1):141. Epub 2023/09/28. doi: 10.1038/s41541-023-00742-7 [pii] 742 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00742-7</ArticleId><ArticleId IdType="pmc">PMC10533894</ArticleId><ArticleId IdType="pubmed">37758751</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami A, Krewski D, Farhat N, Mattison D, Wilson K, Gravel CA, et al.. Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis. BMJ Open. 2023;13(6):e065687. Epub 2023/06/21. doi: 10.1136/bmjopen-2022-065687 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-065687</ArticleId><ArticleId IdType="pmc">PMC10314577</ArticleId><ArticleId IdType="pubmed">37339840</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal V, Mukherjee D, Peng Ang S, Kainth T, Naz S, Babu Shrestha A, et al.. COVID-19 vaccine-associated myocarditis: Analysis of the suspected cases reported to the EudraVigilance and a systematic review of the published literature. Int J Cardiol Heart Vasc. 2023;49:101280. Epub 2023/12/25. doi: 10.1016/j.ijcha.2023.101280 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcha.2023.101280</ArticleId><ArticleId IdType="pmc">PMC10746454</ArticleId><ArticleId IdType="pubmed">38143781</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>